MPACT

NCT00844649 📎

Regimen

Experimental
Nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 d1, 8, 15 q4w.
Control
Gemcitabine 1000 mg/m2 weekly x 7 of 8 weeks then 3 of 4 weeks.

Population

Metastatic PDAC, first-line, KPS ≥70, global multicenter (including patients unfit for FOLFIRINOX — ECOG 2 allowed).

Key finding

MPACT established nab-paclitaxel + gemcitabine as a new 1L metastatic PDAC standard, particularly for patients unable to tolerate FOLFIRINOX (older, ECOG 2, or fragile). The regimen remained the preferred alternative to FFX through NAPOLI-3 (2023), which used it as the control arm.

Source: PMID 24131140

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.42)